NICE recommends further migraine prevention option

Galcanezumab (Emgality) is the second calcitonin gene-related peptide (CGRP) inhibitor to be approved for routine NHS prescribing in patients with chronic migraine.

by Chloe Harman
Elevated blood concentrations of CGRP have been associated with migraine attacks. | GETTY IMAGES
Elevated blood concentrations of CGRP have been associated with migraine attacks. | GETTY IMAGES

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package